RxDoctor Payments DataLook up a doctor →

David Ginsburg, MD

Neurology · Las Vegas, NVNPI 1316905128

Payments from drug & device makers

$28,481in general payments, 2019–2025

Across 929 payments — averaging $30.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$3K
  • Medtronic$3K
  • Argenx US, Inc.$3K
  • UCB, Inc.$2K
  • Lundbeck LLC$917
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)204$3,766
AstraZeneca(2 entities)75$3,078
Medtronic(2 entities)68$2,717
Argenx US, Inc.69$2,506
UCB, Inc.55$1,938
Lundbeck LLC34$917
Biogen25$900
Tanabe Pharma America, Inc.27$858
Boston Scientific12$745
Amgen(2 entities)22$733
SK Life Science, Inc.17$660
Teva Pharmaceuticals USA, Inc.13$581
Takeda Pharmaceuticals U.S.A., Inc.18$574
Grifols Shared Services North America, Inc.7$573
Johnson & Johnson19$563
EDW Pharma, Inc.2$544
Acadia Pharmaceuticals Inc19$447
CSL Behring18$419
Pfizer19$371
Neurocrine Biosciences, Inc.19$358
Avanir Pharmaceuticals, Inc.12$310
Amylyx Pharmaceuticals, Inc.11$253
Alnylam Pharmaceuticals Inc.9$242
Sanofi5$218
Livanova USA, Inc.6$209
Kyowa Kirin, Inc.9$203
Adamas Pharmaceuticals, Inc.6$195
Novartis9$183
Axsome Therapeutics, Inc.2$174
Grifols USA, LLC2$169
Eisai Inc.4$168
Catalyst Pharmaceuticals, Inc.5$163
Abbott4$160
MDD US Operations, LLC8$154
Janssen Scientific Affairs, LLC3$152
Bristol Myers Squibb1$145
Corium, LLC1$125
Ipsen Biopharmaceuticals, Inc5$124
Otsuka America Pharmaceutical, Inc.5$119
ITF Therapeutics LLC4$108
Akcea Therapeutics, Inc.3$107
Strongbridge US Inc.5$107
Xeris Pharmaceuticals, Inc.4$96
Acorda Therapeutics, Inc5$95
ANI Pharmaceuticals, Inc.3$92
Genentech USA, Inc.4$83
Neurelis, Inc.4$80
Merz North America, Inc.4$77
Amneal Pharmaceuticals LLC5$76
Sarepta Therapeutics, Inc.2$61
Merz Pharmaceuticals, LLC2$49
Ultragenyx Pharmaceutical Inc.2$47
Revance Therapeutics, Inc.2$46
Genentech, Inc.1$43
Sunovion Pharmaceuticals Inc.3$41
Cvrx, Inc.1$41
Coloplast2$40
PTC Therapeutics, Inc.1$35
Philips North America LLC1$32
Arbor Pharmaceuticals, Inc.2$32

How this compares

$28,481 in reported general payments places this provider in the 80th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada →

Medicare billing

Part B allowed, 2024
$73,471
Medicare patients
164
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →